|

A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)

RECRUITINGPhase 3Sponsored by Merck Sharp & Dohme LLC
Actively Recruiting
PhasePhase 3
SponsorMerck Sharp & Dohme LLC
Started2026-09-18
Est. completion2032-03-19
Eligibility
Age18 Years+
SexFEMALE
Healthy vol.Accepted
Locations6 sites

Summary

Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard care options may include: Maintenance treatment, which is used after another therapy to keep the cancer from growing, spreading, or coming back. Bevacizumab is a targeted therapy used as standard maintenance treatment. Targeted therapy works to control how specific types of cancer cells grow and spread. Observation, which is watching to see if cancer grows or worsens. The study medicine, raludotatug deruxtecan- R-DXd, is a targeted therapy. The goal of this study is to learn if people who receive R-DXd maintenance treatment with or without bevacizumab live longer without the cancer getting worse than people who receive standard care.

Eligibility

Age: 18 Years+Sex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

* Has a new, histologically confirmed diagnosis of International Federation of Gynecology and Obstetrics (FIGO) Stage III or Stage IV epithelial ovarian cancer (EOC) (high grade serous or high grade endometrioid), fallopian tube cancer, or primary peritoneal cancer
* Has undergone primary debulking surgery (PDS) or interval debulking surgery (IDS)
* Has completed first-line (1L) platinum-based chemotherapy, with a response of stable disease, partial response, complete response or no evidence of disease per protocol
* Has provided tumor tissue that is not previously irradiated
* Who have AEs due to previous anticancer therapies must have recovered to Grade ≤1 or baseline (except alopecia or vitiligo), as assessed by the physician investigator
* Human immunodeficiency virus (HIV)-infected participants must have well-controlled HIV on antiretroviral therapy (ART)

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

* Has non-serous or non-endometrioid high-grade epithelial histology, nonepithelial ovarian cancers, borderline tumors, mucinous tumor, seromucinous tumor that is predominately mucinous, malignant Brenner's tumor, and undifferentiated carcinoma
* Has received 1L platinum-based chemotherapy without bevacizumab and have a response of SD or PR at the time of screening
* Has received prior systemic anticancer therapy, with the exception of the first-line platinum-based chemotherapy required by the inclusion criteria
* Has not recovered from major surgery or has ongoing surgical complications
* Has a homologous recombination deficiency (HRD)-positive, unknown, or inconclusive tumor status as determined by the central laboratory
* Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease
* Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder or prior pneumonectomy
* Has current, clinically relevant bowel obstruction including obstruction related to underlying EOC, abdominal fistula or gastrointestinal perforation, intra-abdominal abscess, or evidence of rectosigmoid involvement by pelvic exam
* HIV-infected participants with a history of Kaposi's sarcoma and/or multicentric Castleman disease
* Has known additional malignancy that is progressing or has required active treatment within the past 3 years
* Has active infection requiring systemic therapy

Conditions5

CancerFallopian Tube CancerOvarian CancerOvarian NeoplasmsPeritoneal Cancer

Interventions2

Locations6 sites

MedStar Washington Hospital Center ( Site 0026)
Washington D.C., District of Columbia, 20010
Study Coordinator202-877-9386
Lahey Hospital & Medical Center ( Site 0031)
Burlington, Massachusetts, 01805
Study Coordinator781-744-3421
Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8000)
Eugene, Oregon, 97401
Study Coordinator541-683-5001
Texas Oncology - Central/South Texas ( Site 8002)
Austin, Texas, 78731
Study Coordinator512-427-9400
Texas Oncology - DFW ( Site 8005)
Study Coordinator817-413-1500

Find trials near these locations

Related trials

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.